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Abstract
Background: To improve the efficacy of bone marrow-derived mesenchymal stem cell (MSC) therapy targeted to infarcted
myocardium, we investigated whether a self-setting silanized hydroxypropyl methylcellulose (Si-HPMC) hydrogel seeded
with MSC (MSC+hydrogel) could preserve cardiac function and attenuate left ventricular (LV) remodeling during an 8-week
follow-up study in a rat model of myocardial infarction (MI).
Methodology/Principal Finding: Si-HPMC hydrogel alone, MSC alone or MSC+hydrogel were injected into the myocardium
immediately after coronary artery ligation in female Lewis rats. Animals in the MSC+hydrogel group showed an increase in
cardiac function up to 28 days after MI and a mid-term prevention of cardiac function alteration at day 56. Histological
analyses indicated that the injection of MSC+hydrogel induced a decrease in MI size and an increase in scar thickness and
ultimately limited the transmural extent of MI. These findings show that intramyocardial injection of MSC+hydrogel induced
short-term recovery of ventricular function and mid-term attenuation of remodeling after MI.
Conclusion/Significance: These beneficial effects may be related to the specific scaffolding properties of the Si-HPMC
hydrogel that may provide the ability to support MSC injection and engraftment within myocardium.
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Introduction
After myocardial infarction (MI), left ventricular (LV)
remodeling occurs with early and progressive extracellular
matrix (ECM) degradation, infarct zone expansion, scar
thinning, LV enlargement and eventually, transition to heart
failure [1,2]. Current anti-remodeling therapies are limited as
they fail to prevent ventricle enlargement [3,4] and morbidity-
mortality remains high [5]. Mesenchymal stem cell (MSC)
injection into the infarcted myocardium is a newly developed
strategy for cardiac tissue repair and regeneration after MI [6].
The beneficial effects of MSC injection have been partly related
to their paracrine activity. MSC secrete angiogenic, anti-
apoptotic, and anti-inflammatory cytokines that may contribute
to the recovery of cardiac function [7,8] and significantly
decrease fibrosis of the myocardium [9,10]. Most MSC
administration strategies use intramyocardial injections of cells
suspended in culture medium. However, this technique is
limited by low cell retention and survival rates. For example,
several studies have shown that more than 80%–90% of grafted
cells die within 72 hours after injection into the myocardium
[11,12]. Multiple mechanisms may contribute to the premature
death of grafted cells, including oxidative stress, hypoxia, and
inflammation [13,14]. Recently, cardiac tissue engineering,
combining cells and scaffolding biomaterials, has emerged as a
promising approach to provide support for tissue repair after
MI [15,16]. Among the various types of biomaterials currently
available, hydrogels comprising hydrophilic, biocompatible
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polymers and peptides may represent excellent cell delivery
systems due to their unique property of permitting in situ gel
formation [17]. There are two major types of hydrogels: natural
hydrogels, such as fibrin glue [18] and alginate [19], and
synthetic hydrogels, such as polyethylene glycol (PEG) [20].
Natural hydrogels are used as scaffolds because they exhibit
several critical biological functions that synthetic polymers lack,
such as cell adhesion and biodegradation. We previously
designed a water-rich hydrogel consisting of silanized hydro-
xypropyl methylcellulose (Si-HPMC) that can be steam sterilized
[21] and supports the diffusion of signaling molecules and
nutrients [22]. Interestingly, this Si-HPMC hydrogel can be
injected together with MSC in vivo and is able to self-crosslink to
form a scaffolding matrix [23].
In this context, and to develop a novel cardiac tissue
engineering strategy, we questioned whether a hydrogel-assisted
intramyocardial injection of bone marrow-derived MSC could
attenuate post-MI cardiac disorders. To address this issue, we used
a rat model to evaluate the effects of injecting Si-HPMC hydrogel
seeded with MSC on cardiac function and LV remodeling in a rat
model of MI.
Results
Rheological Characteristics of Si-HPMC Hydrogel
Rheological properties of Si-HPMC solution mixed with acidic
buffer (1:1) were measured. The final product (Si-HPMC
hydrogel) was a reticulated hydrogel with a pH value of 7.4 after
27.263.4 min. Dynamic rheological measurements were per-
formed to characterize the Si-HPMC hydrogel, including shear
strain measurements to evaluate the storage modulus (G’, which
characterizes the hard component), and the loss modulus (G’’,
which characterizes the liquid component). After three weeks of
cross-linking and completion of the self-setting process, the G’
value was 343.26106.5 Pa and the G’’ was 44.5615.4 Pa. The
compressive modulus (which reflects the stiffness of the material in
a compressive experiment) at a 5% strain was 328.6697.0 Pa.
MSC Characterization and Viability in Three-dimensional
Culture within the Si-HPMC Hydrogel
To characterize MSCs before in vivo injection, the expression of
a number of surface markers [24,25] was assessed by flow
cytometry. No expression of CD34 and CD45 was observed
(Figure 1A). In contrast, MSC expressed CD29, CD54 and CD90
(Figure 1B).
To evaluate whether the Si-HPMC hydrogel was cytotoxic,
MSC viability was monitored in Si-HPMC 3D-culture by confocal
fluorescent microscopy (Figure 1C). MSC viability was assessed by
measurement of green fluorescence intensity, as a consequence of
incorporation of the calcein fluorescent probe into the cytoplasm
(Figure 1D). The results showed that MSC viability was
maintained throughout the experiment.
MSC Tracking in Cardiac Tissue
To determine whether the Si-HPMC hydrogel may allow cell
injection and engraftment in cardiac tissue, MSC were detected
24 h after their implantation using CFSE fluorescence labeling
(Figure 2A and 2B) and CD90 expression in host tissue (Figure 2C).
Because of the possibility of a rapid loss of fluorescence of the
CFSE- labeled MSCs, the red fluorescence of PKH26 was used to
track MSC 14 days after the injection into the cardiac tissue
(Figure 2D). Histological evaluation of the myocardium 24 h after
MSC injection with or without hydrogel showed that most of the
grafted MSC were localized in the left ventricular wall around
injection sites and MSC survived 14 days after the injection into
the left ventricle tissue. These data indicate that Si-HPMC
hydrogel was able to support MSC implantation and engraftment
in cardiac tissue.
Comparative Effects of Hydrogel, MSC, and
MSC+hydrogel on Cardiac Function and LV Remodeling
MI was induced by ligation of the LAD coronary artery in 62
rats. After MI induction, rats were randomized into 4 treatment
groups to receive intramyocardial injections of (1) PBS as the
control, (2) hydrogel, (3) MSC and (4) MSC+hydrogel. In our
study, the overall mortality 24 hours after surgery was 30.767.7%
(19/62 rats) with no significant differences between treatment
groups (Table 1A). Echocardiography was performed 1 day after
coronary artery ligation to exclude rats without a significant MI
(defined as animals with a LVEF .70%; Table 1B). Importantly,
the number of excluded rats was not significantly different between
treatment groups (Table 1B), nor were the parameters of LV
dimensions and function measured at Day 1 of the echocardiog-
raphy follow-up analysis (Table 2).
As expected, MI induced an increase in LV remodeling,
characterized by an increase in LV chamber dimensions, (LVESD
and LVEDD) leading to a decrease in LVFS and LVEF (Figure 2,
PBS conditions). As compared to the PBS group, injections of
hydrogel, MSC or MSC+hydrogel, significantly attenuated the
MI-induced increase in LV end-systolic diameter (LVESD) over
the time period analyzed (Figure 3A). These injections also
preserved the LV end-diastolic diameter (LVEDD) as compared to
the PBS group, but did not improve the LVEDD (Figure 3B). The
injection of hydrogel alone induced a transient but a significant
increase in LVEF at Day 28, but not at Day 7 and Day 56 as
compared to the PBS group. In contrast, MSC injection induced a
significant increase in LVEF at Days 28 and 56 but not at Day 7,
suggesting a delayed effect (Figure 3C). In addition, the LVEF did
not significantly differ between the two groups throughout the
study follow-up, as compared to Day 1. The injection of
MSC+hydrogel during the acute phase of MI induced a significant
increase in LVEF from Day 7 at Day 56 after injection, as
compared to the PBS group, and a significant increase in LVEF as
compared to Day 1 post MI. Interestingly, the LVEF in the
MSC+hydrogel group was higher as compared to that in the MSC
group at Day 7 and as compared to that in the hydrogel group at
Day 56.
Comparative Effects of Hydrogel, MSC or MSC+hydrogel
on Infarct Expansion and Ventricular Fibrosis
Morphometric analyses of heart sections were performed at Day
56 to analyze LV remodeling. For all animals, the infarct area was
located in the anterior region of the left ventricle (Figure 4A). The
MI size was significantly reduced in the hydrogel group, the MSC
group and the MSC+hydrogel group as compared to the PBS
group (Figure 4B). In addition, the size of the MI was also reduced
in the MSC and MSC+hydrogel groups as compared to the
hydrogel group. The percentage of ventricular fibrosis (Figure 3C)
was also significantly reduced in the hydrogel group, the MSC
group, and the MSC+hydrogel group as compared to the PBS
group. Next, the effects of different treatments on the LV wall
were assessed by measuring the relative scar thickness (Figure 5A–
5B). The results showed a significant increase in the relative scar
thickness in the hydrogel, MSC and MSC+hydrogel groups as
compared to the PBS group. The infarct expansion index was
calculated using both MI size and relative scar thickness
parameters (Figure 5C). This index was significantly reduced with
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Figure 1. MSC characterization and viability in 3D culture within the Si-HPMC hydrogel. (A and B) Flow cytometric analysis of MSC for
CD29, CD54, CD90, CD34, CD45 and CD86 expression. 10,000 events were scored. Results are expressed as % of positive cells in the whole population
on representative histogram plots. (C and D) MSC were cultured in 3D Si-HPMC hydrogel for the indicated times. (C) Labeling cells with calcein-AM
(green color) and with EthD-1 (red color) revealed living and dead cells, respectively. Representative samples of MSC cultures visualized by confocal
microscopy. (D) As described in the Materials section, the percentages of living and dead MSC cultured in 3D within hydrogel over 7 days (p=NS as
compared between time points, one-way ANOVA). All values represent mean 6 SEM. Scale bar = 100 mm.
doi:10.1371/journal.pone.0051991.g001
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the injections of hydrogel, MSC and MSC+hydrogel as compared
to the injection of PBS. Interestingly, chondroid metaplasia of the
endocardium (indicated by arrows in Figure 4A) was often
observed in the PBS group (83% of rats) whereas this feature
was visible in only 14% (p,0.05 vs. PBS) of rats in the
Figure 2. Evaluation of MSC engraftment 24 hours and 14 days after in vivo injection with Si-HPMC hydrogel into cardiac tissue.
MSC engraftment 24 hours and 14 days after in vivo MSC+Si-HPMC hydrogel injection into cardiac tissue is shown on representative transversal
histology heart sections. (A, B) Cell nuclei were labeled with To-Pro-3 (red fluorescence). MSC were labeled prior to injection with a fluorescent dye,
CFSE (green fluorescence) and visualized 24 h after the implantation. (C) CD90 staining allowed identification of implanted MSC in left ventricle 24 h
after injection. (D) PKH26 labeled MSC (red fluorescence) in heart wall with DAPI for cell nuclei (blue fluorescence), 14 days after implantation. (A)
Scale bar = 1.5 mm. (B, C and D) scale bar Scale bar = 0.5 mm.
doi:10.1371/journal.pone.0051991.g002
Table 1. Number of animals included in the study.
Animals number at baseline Living animals at day 1
PBS 11 10
hydrogel 14 11
MSC 15 9
MSC+hydrogel 22 13
Total 62 43
Animals number with LVEF.70% at day 1 Animals number with LVEF#70% at day 1
PBS 4 6
hydrogel 4 7
MSC 1 8
MSC+hydrogel 4 9
Total 13 30
(A) Number of animals surviving 1 day post-MI. p= 0.21 (Fisher exact test). (B) Number of animals in the follow-up study with an EF#70% 1 day after MI. p= 0.26 (Fisher
exact test).
doi:10.1371/journal.pone.0051991.t002
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MSC+hydrogel group, 67% of rats in the hydrogel group and 60%
of rats in the MSC group (p=NS).
Discussion
There has been growing interest in the use of scaffolding
biomaterials as a vehicle for delivery of reparative cells to improve
the efficacy of targeted stem cell therapy for myocardial infarction.
Among the biomaterials that have been considered for tissue
engineering and regenerative medicine, hydrogels are probably
the most appropriate synthetic matrices since they exhibit
injectability and cross-linking properties. When considering stem
cell-based cardiac tissue engineering, the ideal hydrogel should be
biocompatible with respect to MSC and cardiac tissue and should
also be injectable into the myocardium to provide the advantage of
minimally invasive delivery [26]. In the present study, our
objective was to investigate whether a self-setting cellulosic
hydrogel seeded with MSC could preserve cardiac function and
prevent LV remodeling during an 8-week follow-up period in a rat
model of MI.
Among the various hydrogels used in cardiac tissue engineering,
we focused our attention on a cellulose derivative hydrogel (Si-
HPMC) that exhibits rheological properties compatible with its
implantation by mini-invasive surgery [27]. The grafting of silanol
groups along the HPMC chains confers this hydrogel with a self-
setting property. The pH-dependent condensation between the
silanol groups allows the Si-HPMC viscous solution to rapidly
transform into Si-HPMC solid gel, leading to the formation of a
3D network. Interestingly, this process does not require any
addition of cross-linking agents that have been extensively
described as potent cytotoxic factors. The gelation time is a
physicochemical parameter that has to be finely tuned, to enable
successful manipulation and injection of the Si-HPMC hydrogel/
cells mixture in situ [28]. Of interest and as previously suggested by
our group, the gelation time of Si-HPMC (about 30 min) is
sufficient to enable cell-hydrogel mixing [29] as well as its injection
in vivo [30]. The need for optimizing hydrogel elasticity has also
been recognized as a physicochemical parameter that governs the
regenerative potential of biomaterials, supporting adequate stem
cell differentiation [31] as well as the mechanical function of the
targeted tissue [32]. Engler et al. defined a range of rigidity for
various tissues measured by the elastic modulus (E). For cardiac
muscle tissue, the E value ranges between 8 and 17 kPa [31]. Of
note, our mechanical data showed that Si-HPMC hydrogel
exhibits an E value of about 0.3 kPa, which is quite lower than
that of cardiac tissue and as such, is unlikely to adversely affect the
mechanical properties of the myocardium. In addition, the
Table 2. Echocardiography measurements at baseline (Bsl) and at 1 day (d1), 7 days (d7), 28 days (d28) and 56 days (d56) after MI.
Parameters PBS (n=6) hydrogel (n =7) MSCs (n=8) MSC+hydrogel (n=9)
LVEDD (mm)
Bsl 5.460.2 5.260.2 5.660.1 5.660.2
d1 5.960.1 5.860.3 6.260.2 6.060.1
d7 6.660.1 6.160.3 6.360.1 6.160.2
d28 7.260.2¥ 6.960.3¥ 7.060.3 6.660.3
d56 7.460.3¥ 7.360.5¥ 7.060.4 6.860.2
LVESD (mm)
Bsl 2.460.1 2.660.2 2.860.1 3.060.2
d1 4.060.1 4.160.3 4.360.1 4.360.2
d7 5.060.1¥ 4.060.3* 4.360.2* 3.960.2*
d28 5.760.3¥ 5.060.3* 5.260.4* 4.360.3*
d56 6.060.3¥ 5.560.5* 4.960.3* 4.860.1*$
LVFS (%)
Bsl 56.661.7 49.462.0 49.561.0 47.162.2
d1 29.062.4 29.962.8 30.461.8 27.961.9
d7 24.160.9 34.162.0* 31.262.5 36.961.7¥*+
d28 20.262.3¥ 28.061.2* 26.763.3* 34.461.9¥*+$
d56 19.661.5¥ 25.662.9* 30.862.4* 29.461.5*$
LVEF (%)
Bsl 87.461.5 86.061.2 86.861.9 88.261.5
d1 61.364.0 64.662.6 64.661.8 61.262.9
d7 55.762.4 68.062.3 63.563.2 76.061.6¥*+
d28 49.062.5¥ 71.762.6* 72.461.5* 76.461.5¥*
d56 47.462.4¥ 56.964.6 65.463.3* 68.562.0*$
LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, ejection fraction; LVFS, fraction shortening.
¥p,0.05 compared to Day 1 post-infarction in the same group, one-way repeated measures ANOVA.
*p,0.001 vs. the PBS group,
$p,0.05 vs. the hydrogel group and,
+p,0.05 vs. the MSC, one-way ANOVA.
All values represent mean 6 SEM.
doi:10.1371/journal.pone.0051991.t001
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formation of a 3D network could provide cells with a protective
environment particularly during the injection and implantation
phase in cardiac tissue. Aguado et al. showed that cell protection is
mainly due to the mechanical and scaffolding properties of
hydrogels [33]. Indeed, crosslinked hydrogels improved cell
viability during the injection in the host tissue compared to non-
crosslinked hydrogels. They have also shown that extensional flow
at the entrance of the syringe needle is the main cause of acute cell
death. These results provide mechanistic insight into the role of
mechanical forces during cell delivery and support the use of
protective hydrogels in future clinical stem cell injection studies.
Other key parameters in the preclinical development of innovative
biomaterial-based regenerative strategies include the biological
properties of biomaterials, such as cytocompatibility. Along these
Figure 3. Evaluation of cardiac function by echocardiography in rats after myocardial infarction (MI). Measurements were performed at
baseline before MI and 1, 7, 28 and 56 days after MI as indicated. (A) Left ventricular end-diastolic diameter (LVEDD). (B) Left ventricular end-systolic
diameter (LVESD). (C) Left ventricular fractional shortening (LVFS). (D) Left ventricular ejection fraction (LVEF). ¥p,0.05 compared to day 1 post-MI in
the same group, one-way repeated measures ANOVA.*p,0.001 vs. the PBS group at the same time-point, $p,0.05 vs. the hydrogel group at the
same time-point and +p,0.05 vs. the MSC group at the same time-point, one-way ANOVA. All values represent mean 6 SEM.
doi:10.1371/journal.pone.0051991.g003
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lines, whereas Si-HPMC has been largely described as being
cytocompatible with both osteogenic [34] and chondrogenic cells
[29], the data reported in the current study additionally indicate
that Si-HPMC supports the 3D viability of bone marrow-derived
MSC.
In light of these data, we logically embarked on in vivo
experiments to determine the beneficial effects of injecting either
hydrogel alone, MSC alone or MSC-seeded hydrogel, on the
cardiac parameters of infarcted rat hearts. LV dysfunction and
remodeling after MI are major determinants of transition to heart
failure and cardiac mortality [4,35]. We thus evaluated LV
dysfunction by determining the LV ejection fraction (LVEF). The
LV diameters, infarct size, LV fibrosis and scar thickness were
then assessed to determine LV remodeling. Over the past decade,
several studies have documented the cardioprotective effects of
injecting hydrogels alone. For instance, the intramyocardial
injection of alginate hydrogel [36] or fibrin glue [37] has been
proposed as an effective acellular strategy to prevent adverse
cardiac remodeling and dysfunction after MI in rats. Interestingly,
in our study, the injection of Si-HPMC hydrogel alone affected the
LV function mainly during the first 4 weeks after MI, with a
progressive decrease thereafter. Taken together, these data suggest
that the injection of hydrogel primarily preserves short-term
cardiac function but is probably insufficient to prevent long-term
heart failure. Similar results were observed in other studies using
non-degradable hydrogels. Dobner et al., injected a non-degrad-
able PEG into the infarct immediately after MI and showed that
there was temporary retardation of LV remodeling at early time
points, but not at later time points [38]. Rane et al. demonstrated
recently that passive structural reinforcement alone was insuffi-
cient to prevent post-MI remodeling, suggesting that bioactivity
and/or cell infiltration due to degradation of injectable materials
are likely playing a key role in the preservation of cardiac function
[39]. The mechanism underlying the transient effect of hydrogel
Figure 4. Evaluation of myocardial infarction size and left ventricular fibrosis. (A) Representative transversal histology sections of heart
and Masson trichrome staining for infarct size measurement at day 56 after MI. Collagen-rich areas (scar tissue) are colored in blue and healthy
myocardium in red. Scale bar = 1.5 mm. (B) Percentage of circumferential infarct size (MI size) divided by total LV tissue, and (C) percentage of fibrosis
in total LV tissue. For (B) and (C): *p,0.05 and **p,0.001 vs. the PBS group, $p,0.05 and $$p,0.001 vs. the hydrogel group, one-way ANOVA. LV, left
ventricle; RV, right ventricle. All values represent mean 6 SEM.
doi:10.1371/journal.pone.0051991.g004
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injected in situ may be related to the capability of hydrogels to
increase scar thickness and stabilize the early infarct, by providing
scaffolding and critical physical support to the LV wall [16]. The
loss of long term efficacy could possibly be due to the absence of
uniformity in polymer spread allowing for regional and global
function abnormalities, as well as infarct expansion in areas where
the polymer was not present. Further studies are needed to fully
understand the effects of polymer spread and stiffness on infarct
expansion and deterioration of cardiac function [40].
Our results showed that intramyocardial injection of MSC gives
an optimal therapeutic benefit starting 4 weeks after MI. In past,
numerous preclinical studies reported that intramyocardial trans-
plantation of MSC after acute myocardial infarction improved
cardiac function and decreased infarct size several weeks after
MSC injection [41,42,43]. The recent review of Elnakish et al.
reported the effects of MSC therapy on mice, rats and large
animal models of MI. In rat models of acute MI, the improving
LVEF was mainly observed starting from 4 weeks and up to 8
weeks [44]. The delayed effect of MSC after implantation may be
due to the hypoxia, inflammation and loss of ECM support in
infarcted cardiac tissue that probably lead to a poor MSC
engraftment [45]. Given the short-term effect of Si-HPMC
hydrogel and the delayed effect of MSC, we associated our
hydrogel with MSC in order to determine whether this association
may be beneficial, not only in the short-term but also in the mid-
term, to prevent the detrimental consequences of MI. As expected,
our results showed that the co-injection of Si-HPMC hydrogel and
MSC has a marked short and mid-term effect on LV function and
remodeling. Of particular interest, the co-injection of Si-HPMC
and MSC had a more prominent effect during the first 7 day-acute
phase period as compared to the injection of hydrogel alone.
Considering that stem cells, such as MSC, normally reside in
‘‘niches’’, complex 3D environments regulated by physical
interactions and soluble factors [46], one can assume that hydrogel
may be able to simulate this microenvironment, thereby providing
cells with a protective ‘‘niche’’. In support of this hypothesis,
several reports have indicated that hydrogels made of fibrin or
polyethylene glycol may be able to increase the survival and
retention of intramyocardial transplanted cells and further
improve the impaired cardiac function compared to MSC alone
[47,48]. Whether our cellulose derivative Si-HPMC hydrogel can
Figure 5. Evaluation of scar thickness and infarct expansion. (A) Representative photomicrographs of Masson trichrome staining of the scar
area (collagen-rich areas in blue and healthy myocardium in red). The double arrow depicts the LV wall (epi, epicardium; endo, endocardium). The
arrows show chondroid metaplasia of the endocardium. Scale bar = 0.5 mm. (B) Relative scar thickness (scar thickness/wall thickness). (C) Infarct
expansion index ([LV cavity area/whole LV area]/relative scar thickness). For (B) and (C): *p,0.05 and **p,0.001, one-way ANOVA. All values represent
mean 6 SEM.
doi:10.1371/journal.pone.0051991.g005
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provide cells with such a favorable environment with appropriate
mechanical and biological stimuli requires further investigation.
In addition to the echocardiography parameters used to assess
LV function and remodeling after MI, such as LVEF and LVFS,
histological analyses may also provide further insight into the tissue
changes that occur. It is recognized for a long time that the
presence of focal endocardial metaplasia, consisting of chondroid
tissue in areas of transmural scarring, reflects the severity of MI
[49,50]. Accordingly, the intramyocardial administration of Si-
HPMC hydrogel seeded with MSC was found to limit the extent of
transmural MI, preserve endocardial myocytes and reduce
metaplasia. These data strengthen our hypothesis that the
intramyocardial injection of hydrogel and MSC may be a relevant
strategy to prevent the short-term and mid-term deleterious effects
of MI on ventricular remodeling.
Despite promising results, this study exhibits limitations. First,
the experiments were designed to evaluate whether a hydrogel-
assisted intramyocardial injection of bone marrow-derived MSC
could attenuate post-MI cardiac disorders. However, this study did
not allow deciphering the mechanisms explaining the beneficial
effects of this treatment on cardiac function particularly at short-
term after myocardial infarction. Secondly, histological experi-
ments showed persistence of labeled MSC injected with hydrogel
until 14 days, with cell morphology similar to MSC injected alone.
Unfortunately we were not able to quantitatively compare MSC
survival in hearts transplanted with MSC with or without
hydrogel. Nevertheless, cell survival may not be the solely
mechanism underlying the effect of the hydrogel injected in situ,
as this one may rely on capability of hydrogels to increase scar
thickness and stabilize the early infarct, by providing scaffolding
and critical physical support to the left ventricular wall. While a
previous study performed in bone tissue suggest that the Si-HPMC
hydrogel underwent phagocytosis from the edge to the center of
the implantation site at 8 weeks after implantation in host tissue
[51], the degradation kinetics of Si-HPMC hydrogel in cardiac
tissue remains to be determined. Finally, to limit the animal
number in accordance with the ethical committee, we did not
include a sham animal group. Nevertheless, numerous previous
animal studies showed that left thoracotomy alone does not alter
cardiac function and morphology on the long term [52].
In summary, we have demonstrated that intramyocardial
injection of a self-setting cellulose derivative hydrogel seeded with
MSC induced short-term recovery of ventricular function and
mid-term prevention of remodeling in a rat model of coronary
artery ligation-induced MI. In the future, it should be defined
whether these beneficial effects may be related to the specific
scaffolding properties of the Si-HPMC hydrogel that may provide
it with the ability to support MSC injection and engraftment
within the cardiac tissue. Together with a catheter-based cell
delivery system [53], the use of an injectable scaffolding hydrogel
offers the possibility to prevent the damaging consequences of MI.
Materials and Methods
Isolation, Culture and Characterization of Bone Marrow
Mesenchymal Stem Cells
Bone marrow (BM) was obtained from female Lewis rats
weighing 180–200 g (Janvier, France). BM from the femur cavity
was flushed with a-MEM medium (Invitrogen corporation,
Paisley, U.K.) containing 10% FCS (Hyclone Perbio, Thermo
Fisher Scientific), 1% L-Glutamine, 1% penicillin/streptomycin
(Invitrogen) and 2 ng/mL of human basic FGF2 (AbCys, Paris,
France). The cell suspension was centrifuged (1,200 rpm, 7 min)
and cells were plated in culture flasks (200,000 cells/cm2). Non
adherent cells were removed after 72 h. MSC were recovered by
their capacity to strongly adhere to plastic culture dishes without
cell sorting. MSC were routinely cultured and characterized by
flow cytometry at passage 3 using anti-rat CD90, CD29 FITC-
conjugated antibodies and anti-rat CD45, CD34, CD54, CD86
PE- conjugated. Immediately before in vivo injection, the adherent
MSC were detached with trypsin-EDTA, centrifuged for 1 min at
1,200 g, and resuspended in PBS-BSA (0.1%). Aliquots containing
2.105 MSC were incubated with primary antibodies for 30 min at
4uC. The suspended MSC were washed and then analyzed with a
LSRI fluorescence-activated cell sorter (Becton Dickinson). For
each sample, 10,000 events were acquired and analyzed with
CellQuestTMPro software. Results were expressed as the percent-
age of positive cells by comparison with the isotype-matched
negative control antibodies on histogram plots.
Silanized Hydroxypropyl Methylcellulose-based Hydrogel
Preparation
Synthesis of Si-HPMC hydrogel. Hydroxypropyl methyl-
cellulose (HPMC E4MH) was purchased from Colorcon-Down
chemical (Bougival, France). Si-HPMC was synthesized by mixing
silicium 0.5% (w/v) with HPMC to form a heterogeneous
medium, as previously described [21]. Si-HPMC was solubilized
in 0.2 M NaOH (3%) under constant stirring for 48 h at room
temperature. The solution was dialyzed against 0.09 M NaOH
using 6–8 kDa dialysis tubes (SpectraPor 1, Thermo Fisher
Scientific, France). The resulting viscous solution (pH 12.6) was
sterilized by autoclaving and then mixed using luer-lock syringes
with sterile 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
buffer (HEPES, pH 3.6; Sigma-Aldrich, St Louis, USA) at a
volume ratio of 1:1 as previously described [21]. The final product
was a hydrogel (pH 7.4) containing 1.5% Si-HPMC.
Rheological and mechanical measurements. Cross-link-
ing of 1 ml Si-HPMC hydrogel was induced in 12-well plates.
Dynamic rheological measurements were performed with a
rotational rheometer (Rheostress 300, ThermoHaakeH, Germany)
using a coni-cylindrical geometry with a diameter of 60 mm and a
cone angle of 1u. A multi-wave procedure was performed with 3
frequencies of 1, 3.2 and 10 Hz, with an imposed stress of 1 Pa.
Oscillation tests measuring storage modulus (G’) and loss modulus
(G’’) were performed to study the self-setting process and gel point.
Gel points, given as the time taken for the liquid (G’’.G’) to turn
into a solid (G’.G’’), were evaluated according to the derived
percolation theory [28]. Shear strain measurements were per-
formed on 9 samples with a Haake mars. Frequencies were applied
at a fixed total shear stress (1Pa) and 0.21N. Oscillation tests were
performed to measure G’ and G’’ after 3 weeks of gelation. The Si-
HPMC hydrogel compressive modulus was measured using a TA
HD-Plus (Stable Micro Systems). Six samples were tested after
three weeks of cross-linking and the compressive modulus was
calculated on the basis of strain change from 0 to 5%.
Cell viability in three dimensional culture. Three-dimen-
sional MSC viability was quantitatively assessed by Live & Dead
assays (Invitrogen, France) followed by confocal imaging. MSC
viability was assessed by measurement of fluorescence intensity
using ImageJ (NIH) software. Briefly, MSC were trypsinized and
immediately mixed with Si-HPMC hydrogel at a final concentra-
tion of 106 cells/mL. They were then molded into ultra-low
attachment 24-well plates and incubated at 37uC for 1 h to allow
for the hydrogel to crosslink. Culture medium was then added and
the MSC were cultured within the hydrogel for 24 h, 48 h and
7 days. Live & Dead assays were performed according to the
manufacturer instructions (Invitrogen). Briefly, culture medium
was replaced by fresh culture medium supplemented with 5 mM
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calcein-AM and 2 mM ethidium homodimer-1. After 10 min, the
dye mixture was removed and the hydrogel was thoroughly rinsed
with PBS, before being analyzed with a Nikon A1R confocal laser-
scanning microscope (Nikon France) equipped with an argon laser
(488 nm) and a laser diode (561 nm).
Images were recorded in 5126512 pixels with an objective CFI
Plan Fluor ELWD 40X objective. For each sample, 6 random
positions were chosen within the hydrogel, and a stack of 100
planes were taken from these 6 positions along the z axis using a
10 mm step size. Images obtained per sample were analyzed using
ImageJ (NIH) software with the ‘‘3D object counter’’ plug-in. Each
condition was tested in triplicate, and each experiment was
repeated three times.
In vivo cell tracking. To track MSC after intramyocardial
injection with Si-HPMC hydrogel, 36106 MSC were labeled
in vitro immediately before injection using a green intracellular
fluorescent dye, CFSE (carboxy-fluorescein diacetate succinimidyl
ester, Molecular Probes, concentration 5 mM) as previously
described [54] or the PKH26 Fluorescent Cell Linker Kits for
General Cell Membrane Labeling (Sigma-Aldrich, PKH26GL,
concentration 461026 M). Cell labeling was verified by fluores-
cence microscopy before injection. 24 hours after in vivo injection
of a 150 ml solution containing MSC and Si-HPMC hydrogel, rats
were sacrificed and heart harvested for histological analysis.
Paraffin embedded sections of 5 mm were counterstained with To-
Pro-3 (Invitrogen, T3605) or Vectashield Mounting Medium with
DAPI (Vector Laboratories, H-1200). For MSC specific detection,
sections were successively incubated (90 min, room temperature)
with biotin rat monoclonal anti-CD90 antibody diluted 1:100
(CEDARLANE, CL005B) and HRP-streptavidin with 2-Solution
DAB kit (Invitrogen).
Induction of myocardial infarction in rats and
implantation. Animal studies were performed the agreement
of the regional Animal Ethics Committee (CREEA, ‘‘Comite´
re´gional d’e´thique en matie`re d’expe´rimentation animale’’).
Myocardial infarction was induced by coronary artery ligation
and intramyocardial injections were performed as previously
described [54]. In brief, Female Lewis congenic rats (180–190 g,
Janvier) were anesthetized with a mix of isoflurane/oxygen
inhalation (3%/97%), intubated and ventilated (Harvard Rodent
Ventilator, Harvard Apparatus). A left lateral thoracotomy in the
fourth intercostal space was performed to expose the anterior
surface of the heart. The proximal left anterior descending (LAD)
coronary artery was ligated with a 6.0 polypropylene snare
(Ethicon). The area displaying tissue blanching and wall motion
akinesis was identified as the infarct. Immediately after coronary
artery ligation, 150 ml of a solution containing Si-HPMC hydrogel
alone (hydrogel), MSC alone (36106 cells) in PBS, a combination
of MSC and Si-HPMC hydrogel (MSC+hydrogel), or PBS (used as
the control) were injected into the myocardium using a 26-gauge
needle. A final volume of 150 ml was delivered to 3 injection sites
surrounding the infarcted area.
Echocardiography measurements. Echocardiography
measurements were performed 1 day before MI induction
(baseline), and 1, 7, 28, and 56 days after MI, in anesthetized
rats (2% isoflurane inhalation) using a General Electric Vivid 7VR
(GE Medical System; Milwaukee, WI, USA) equipped with a 13-
MHz transducer. Left ventricular end-diastolic diameter
(LVEDD), LV end-systolic diameter (LVESD), and LV fractional
shortening (LVFS) were recorded from the parasternal long-axis
M-mode images using averaged measurements from 3 to 5
consecutive cardiac cycles in accordance with the American
Society of Echocardiography guidelines [55]. Left ventricular end-
diastolic and end-systolic volumes (LVEDV and LVESV) were
calculated from bidimensional long-axis parasternal views taken
through the infarcted area by means of the single-plane area-
length method [56]. The LV ejection fraction (LVEF) was
calculated as follows: LVEF= (LVEDV-LVESV)/LVEDV)6100.
Histopathology. Rat hearts were recovered, washed in PBS
and fixed in 10% formalin. Hearts were then embedded in
paraffin and 6 mm sections were cut from the apex to the level just
below the ligation site. Three evenly spaced sections were stained
with Masson trichrome and observed with a Nikon TE2000-E
inverted microscope.
The circumferential extent of the scar to total LV tissue [57],
relative scar thickness, and infarct expansion index [58] were
quantified as previously described using ImageJ software (NIH).
The average epicardial and endocardial infarct ratios were
calculated for each section based on the measurement of epicardial
and endocardial infarct lengths and epicardial and endocardial LV
circumferences. For each heart, the infarct size was calculated as
the mean value for the 3 analyzed sections.
Scar and septum thickness were measured at 3 different random
sites and relative scar thickness was calculated as the mean scar
thickness/septum thickness. The infarct expansion index was
calculated as the LV cavity area/(whole LV area/relative scar
thickness). The percentage area of fibrosis in the remote left
ventricle was quantified using in-house image analysis software
based on the equation: %fibrosis = fibrotic area/(fibrotic area+-
non-fibrotic area) [57].
Statistical Analysis. All values are shown as mean6SEM.
Comparison of means was performed using one-way ANOVA
followed by a post-hoc test when appropriate (Fisher’s projected
least significant difference). Frequency comparisons were per-
formed using the Fisher exact test. Echocardiography parameters
measured during the 8-week follow-up period were compared
between groups using one-way ANOVA and within groups using
one-way repeated measures ANOVA. Comparisons were followed
by post hoc tests when appropriate. p,0.05 was selected as the
threshold for statistical significance. All tests were carried out using
SigmaStat 3.5 software for Windows.
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